This book presents a comprehensive and up-to-date account of synthetic approaches in antifungal drug discovery. Addressing the growing threat of drug-resistant fungal infections, it explores how synthetic molecules can serve as effective alternatives or complements to existing antifungal therapies. Bridging medicinal chemistry with clinical relevance, the book offers a multidisciplinary perspective spanning molecular design to real-world therapeutic applications.
Fungal infections continue to pose a significant global health challenge, particularly among immunocompromised individuals. Current antifungal therapies are limited by toxicity, a narrow spectrum of activity, and the rapid emergence of resistance. Synthetic molecules offer exciting opportunities for innovation because they can be rationally designed to target novel fungal pathways with enhanced specificity, efficacy, and safety. This book captures the rapidly evolving landscape of antifungal research by integrating global advances aimed at overcoming these therapeutic challenges.
The chapters are organized in a logical progression, beginning with antifungal resistance mechanisms and drug repurposing strategies, followed by detailed discussions on synthetic scaffolds, medicinal chemistry approaches, computational drug design tools such as molecular docking and QSAR, and concluding with translational aspects including preclinical evaluation, formulation development, and commercialization. The broad range of synthetic chemotypes and therapeutic strategies covered provides readers with a comprehensive and practical understanding of modern antifungal drug discovery.
This book will serve as an authoritative reference for medicinal chemists, microbiologists, pharmaceutical scientists, pharmacologists, infectious disease researchers, and professionals engaged in antifungal drug discovery and development. It equips the next generation of scientists and healthcare innovators with the knowledge required to advance the development of safer and more effective antifungal therapeutics.
